Pelvic malignacy: Integrating form and function

British Journal of Radiology

Volumn 78, Issue SPEC. ISS. 2, 2005, Pages

  Dzik Jurasz, A S K ^a  

^a EPIX Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; HUMAN; IMAGE ANALYSIS; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PELVIS CANCER; BLOOD FLOW; CELL DEATH; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE EXPRESSION; IMAGE PROCESSING; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PELVIS TUMOR; PHARMACOLOGY; POSITRON EMISSION TOMOGRAPHY; VASCULARIZATION;

TUMOR MARKER;

CELL DEATH; FEMALE; GENE EXPRESSION; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PELVIC NEOPLASMS; PHARMACOLOGY; POSITRON-EMISSION TOMOGRAPHY; REGIONAL BLOOD FLOW; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 29644433779     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/75936537     Document Type: Article

References (55)

1. Fuchs VR, Sox HC Jr. Physicians' views of the relative importance of thirty medical innovations. Health Aff (Millwood) 2001;20:30-42.
2. Husband JE, Gwyther SJ, Rankin S. Monitoring tumor response. Abdom Imaging 1999;24:618-21.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
4. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001;219:316-33.
5. Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer 2002;2:11-8.
6. Pralhad T, Madhusudan S, Rajendrakumar K. Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. J Pharm Pharmacol 2003;55:1045-53.
7. Brower V. Tumor angiogenesis - new drugs on the block. Nat Biotechnol 1999;17:963-8.
8. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
9. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM. MRI of the tumor microenvironment. J Magn Reson Imaging 2002;16:430-50.
10. Mattern J. Drug resistance in cancer: a multifactorial problem. Anticancer Res 2003;23:1769-72.
11. Tannock IF. Tumor physiology and drug resistance. Cancer Metastasis Rev 2001;20:123-32.
12. Fojo T. Cancer, DNA repair mechanisms, and resistance to chemotherapy. J Natl Cancer Inst 2001;93:1434-6.
13. Padhani AR, Neeman M. Challenges for imaging angiogenesis. Br J Radiol 2001;74:886-90.
14. Padhani AR, Dzik-Jurasz A. Perfusion MR imaging of extracranial tumor angiogenesis. Top Magn Reson Imaging 2004;15:41-57.
15. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003;9:713-25.
16. Greaves M. Cancer causation: the Darwinian downside of past success? Lancet Oncol 2002;3:244-51.
17. Brown G, Kirkham A, Williams GT, Bourne M, Radcliffe AG, Sayman J, et al. High-resolution MRI of the anatomy important in total mesorectal excision of the rectum. AJR Am J Roentgenol 2004;182:431-9.
18. Brown G, Radcliffe AG, Newcombe RG, Dallimore NS, Bourne MW, Williams GT. Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 2003;90:355-64.
19. Brown G, Richards CJ, Bourne MW, Newcombe RG, Radcliffe AG, Dallimore NS, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 2003;227:371-7.
20. Brown G, Richards CJ, Newcombe RG, Dallimore NS, Radcliffe AG, Carey DP, et al. Rectal carcinoma: thin-section MR imaging for staging in 28 patients. Radiology 1999;211:215-22.
21. Lauffer RB. Paramagnetic metal-complexes as water proton relaxation agents for NMR imaging - theory and design. Chem Rev 1987;87:901-27.
22. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988;48:2641-58.
23. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-51.
24. Jain RK. Delivery of molecular and cellular medicine to solid tumors. J Controlled Release 1998;53:49-67.
25. Mardor Y, Roth Y, Ochershvilli A, Spiegelmann R, Tichler T, Daniels D, et al. Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI. Neoplasia 2004;6:136-42.
26. Dzik-Jurasz A, Domenig C, George M, Wolber J, Padhani A, Brown G, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002;360: 307-8.
27. Hall DE, Moffat BA, Stojanovska J, Johnson TD, Li Z, Hamstra DA, et al. Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res 2004;10:7852-9.
28. Jennings D, Hatton BN, Guo J, Galons JP, Trouard TP, Raghunand N, et al. Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia 2002;4:255-62.
29. Smith ICP, Stewart LC. Magnetic resonance spectroscopy in medicine: clinical impact. Prog Nucl Mag Res Sp 2002;40:1-34.
30. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992;5:303-24.
31. Wolf W, Presant CA, Waluch V. 19F-MRS studies of fluorinated drugs in humans. Adv Drug Deliv Rev 2000;41:55-74.
32. Wheeler-Kingshott CA, Thomas DL, Lythgoe MF, Guilfoyle D, Williams SR, Doran SJ. Burst excitation for quantitative diffusion imaging with multiple b-values. Magn Reson Med 2000;44:737-45.
33. George ML, Dzik-Jurasz AS, Padhani AR, Brown G, Tait DM, Eccles SA, et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg 2001;88:1628-36.
34. Horwich A. Cancer Research Campaign review of radiobiology research. Br J Cancer 1993;67:198-201.
35. Dzik-Jurasz AS, Murphy PS, George M, Prock T, Collins DJ, Swift I, et al. Human rectal adenocarcinoma: demonstration of 1H-MR spectra in vivo at 1.5 T. Magn Reson Med 2002;47:809-11.
36. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004;5:101-6.
37. Hochachka PW, Rupert JL, Goldenberg L, Gleave M, Kozlowski P. Going malignant: the hypoxia-cancer connection in the prostate. Bioessays 2002;24:749-57.
38. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
39. Semenza GL. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 2003;54:17-28.
40. Galbraith SM, Lodge MA, Taylor NJ, Rustin GJ, Bentzen S, Stirling JJ, et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002;15:132-42.
41. Collins DJ, Padhani AR. Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Mag 2004;23:65-83.
42. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol 2003;76 Spec No 1:S87-91.
43. Parker GJ, Tofts PS. Pharmacokinetic analysis of neoplasms using contrast-enhanced dynamic magnetic resonance imaging. Top Magn Reson Imaging 1999;10:130-42.
44. Padhani AR. Functional MRI for anticancer therapy assessment. Eur J Cancer 2002;38:2116-27.
45. Padhani AR. MRI for assessing antivascular cancer treatments. Br J Radiol 2003;76 Spec No 1:S60-80.
46. Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 2004;53:153-9.
47. Kabore AF, Johnston JB, Gibson SB. Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications. Curr Cancer Drug Targets 2004;4:147-63.
48. Hakumaki JM, Poptani H, Puumalainen AM, Loimas S, Paljarvi LA, Yla-Herttuala S, et al. Quantitative 1H nuclear magnetic resonance diffusion spectroscopy of BT4C rat glioma during thymidine kinase-mediated gene therapy in vivo: identification of apoptotic response. Cancer Res 1998;58:3791-9.
49. Niculescu-Duvaz I, Springer CJ. Introduction to the background, principles, and state of the art in suicide gene therapy. Methods Mol Med 2004;90:1-27.
50. Niculescu-Duvaz D, Niculescu-Duvaz I, Springer CJ. Design of prodrugs for suicide gene therapy. Methods Mol Med 2004;90:161-202.
51. Niculescu-Duvaz I, Cooper RG, Stribbling SM, Heyes JA, Metcalfe JA, Springer CJ. Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Opin Mol Ther 1999;1:480-6.
52. Stegman LD, Rehemtulla A, Beattie B, Kievit E, Lawrence TS, Blasberg RG, et al. Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc Natl Acad Sci USA 1999;96:9821-6.
53. Shah K, Jacobs A, Breakefield XO, Weissleder R. Molecular imaging of gene therapy for cancer. Gene Ther 2004;11:1175-87.
54. Shoemaker RH, Scudiero DA, Melillo G, Currens MJ, Monks AP, Rabow AA, et al. Application of high-throughput, molecular-targeted screening to anticancer drug discovery. Curr Top Med Chem 2002;2:229-46.
55. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42.